Management of aggression, agitation, and psychosis in dementia: Focus on atypical antipsychotics

American Journal of Alzheimer's Disease and other Dementias

Volumn 21, Issue 2, 2006, Pages 101-108

  Aupperle, Peter ^a  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

Atypical antipsychotic; BPSD; Dementia

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; FLUOXETINE; GALANTAMINE; HALOPERIDOL; LORAZEPAM; MEMANTINE; NEUROLEPTIC AGENT; OLANZAPINE; PROMAZINE; QUETIAPINE; RISPERIDONE;

AGGRESSION; AGITATION; ANOREXIA; BEHAVIOR DISORDER; CAREGIVER; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DEMENTIA; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FALLING; GAIT DISORDER; HEALTH CARE COST; HUMAN; INJURY; MENTAL DISEASE; META ANALYSIS; PERIPHERAL EDEMA; PSYCHOSIS; PURPURA; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SOMNOLENCE; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; URINARY TRACT INFECTION; URINE INCONTINENCE; WEIGHT GAIN;

EID: 33645774830     PISSN: 15333175     EISSN: None     Source Type: Journal    
DOI: 10.1177/153331750602100209     Document Type: Review

References (64)

1. Finkel SI: Introduction to behavioral and psychological symptoms of dementia (BPSD). Int J Geriatr Psychiatry. 2000; 15(Suppl 1): S2-S4.
2. Small GW, Rabins PV, Barry PP, et al: Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA. 1997; 278: 1363-1371.
3. Finkel SI: Behavioral and psychological symptoms of dementia: A current focus for clinicians, researchers, and caregivers. J Clin Psychiatry. 2001; 62(Suppl 21): 3-6.
4. Hemels ME, Lanctot KL, Iskedjian M, et al.: Clinical and economic factors in the treatment of behavioral and psychological symptoms of dementia. Drugs Aging. 2001; 18: 527-550.
5. Cummings JL, Mega M, Gray K, et al.: The Neuropsychiatrice Inventory: Comprehensive assessment of psychopathology in dementia. Neurology. 1994; 44: 2308-2314.
6. Cohen-Mansfield J: Nonpharmacologic interventions for inappropriate behaviors in dementia. Am J Geriatr Psychiatry. 2001; 9: 361-381.
7. McShane RH: What are the syndromes of behavioral and psychological symptoms of dementia? Int Psychogeriatr. 2000; 12(Suppl 1): 147-153.
8. Tariot PN, Blazina L: The psychopathology of dementia. In Morris TC (ed): Handbook of Dementing Illnesses. New York: Marcel Dekker, 1994.
9. Steele C, Rovner B, Chase GA, et al.: Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry. 1990; 147: 1049-1051.
10. Balestreri L, Grossberg A, Grossberg GT: Behavioral and psychological symptoms of dementia as a risk factor for nursing home placement. Int Psychogeriatr. 2000; 12(Suppl 1): 59-62.
11. Teri L, Rabins P, Whitehouse P, et al.: Management of behavior disturbance in Alzheimer disease: Current knowledge and future directions. Alzheimer Dis Assoc Disord. 1992; 6: 77-88.
12. Herrmann N, Lanctot KL, Naranjo CA: Behavioural disorders in demented elderly patients. CNS Drugs. 1996; 6: 280-300.
13. De Deyn PP, Wirshing WC: Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia. J Clin Psychiatry. 2001; 62(Suppl 21): 19-22.
14. Reisberg B, Borenstein J, Salob SP, et al.: Behavioral symptoms in Alzheimer's disease: Phenomenology and treatment. J Clin Psychiatry. 1987; 48(Suppl): 9-15.
15. Cohen-Mansfield J: Conceptualization of agitation: Results based on the Cohen-Mansfield Agitation Inventory and the Agitation Behavior Mapping Instrument. Int Psychogeriatr. 1996; 8(Suppl 3): 309-315.
16. Dahlke F, Lohaus A, Gutzmann H: Reliability and clinical concepts underlying global judgments in dementia: Implications for clinical research. Psychopharmacol Bull. 1992; 28: 425-432.
17. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep. 1962; 10: 799-812.
18. Herrmann N: Recommendations for the management of behavioral and psychological symptoms of dementia. Can J Neurol Sci. 2001; 28(Suppl1): S96-S107.
19. Sink KM, Holden KF, Yaffe K: Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence. JAMA. 2005; 293: 596-608.
20. Gauthier S, Feldman H, Hecker J, et al.: Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int Psychogeriatr. 2002; 14: 389-404.
21. Paleacu D, Mazeh D, Mirecki I, et al.: Donepezil for the treatment of behavioral symptoms in patients with Alzheimer's disease. Clin Neuropharmacol. 2002; 25: 313-317.
22. Weiner MF, Martin-Cook K, Foster BM, et al.: Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients. J Clin Psychiatry. 2000; 61: 487-492.
23. Tariot PN, Cummings JL, Katz IR, et al.: A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc. 2001; 49: 1590-1599.
24. Wilcock G, Howe I, Coles H, et al.: A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging. 2003; 20: 777-789.
25. Suh GH, Yeon Jung H, Uk Lee C, et al.: A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population. Clin Therap. 2004; 26: 1608-1618.
26. Cummings JL, Schneider L, Tariot PN, et al.: Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatry. 2004; 161: 532-538.
27. Tariot PN, Solomon PR, Morris JC, et al.: A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology. 2000; 54: 2269-2276.
28. Schneider LS, Pollock VE, Lyness SA: A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc. 1990; 38: 553-563.
29. Zaudig M: A risk-benefit assessment of risperidone for the treatment of behavioral and psychological symptoms in dementia. Drug Safety. 2000; 23: 183-195.
30. Lawlor B, Bhriain SN: Psychosis and behavioral symptoms of dementia: Defining the role of neuroleptic interventions. Int J Geriatr Psychiatry. 2001; 16(Suppl 1): S2-S6.
31. Jeste DV, Rockwell E, Harris MJ, et al.: Conventional vs newer antipsychotics in elderly patients. Am J Geriatr Psychiatry. 1999; 7: 70-76.
32. Katz IR, Jeste DV, Mintzer JE, et al.: Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial. J Clin Psychiatry. 1999; 60: 107-115.
33. De Deyn PP, Rabheru K, Rasmussen A, et al.: A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology. 1999; 53: 946-955.
34. Chan WC, Lam LC, Choy CN, et al.: A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioral and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry. 2001; 16: 1156-1162.
35. Brodaty H, Ames D, Snowdon J, et al.: A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry. 2003; 64: 134-143.
36. Suh GH, Son HG, Ju YS, et al.: A randomized, double-blind, crossover comparison of risperidone and haloperidol in Korean dementia patients with behavioral disturbances. Am J Geriatr Psychiatry. 2004; 12: 509-516.
37. De Deyn PP, Katz IR, Brodaty H, et al.: Management of agitation, aggression, and psychosis associated with dementia: A pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone. Clin Neurol Neurosurg. 2005; 107: 497-508.
38. Street JS, Clark WS, Gannon KS, et al.: Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2000; 57: 968-976.
39. De Deyn PP, Carrrasco MM, Deberdt W, et al.: Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2004; 9: 115-126.
40. Clark WS, Street JS, Feldman PD, et al.: The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease. J Clin Psychiatry. 2001; 62: 34-40.
41. Rainer MK, Mucke HA, Kruger-Rainer C, et al.: Zotepine for behavioral and psychological symptoms in dementia: An open-label study. CNS Drugs. 2004; 18: 49-55.
42. Fujikawa T, Takahashi T, Kinoshita A, et al.: Quetiapine treatment for behavioral and psychological symptoms in patients with senile dementia of Alzheimer type. Neuropsychobiology. 2004; 49: 201-204.
43. Scharre DW, Chang SI: Cognitive and behavioral effects of quetiapine in Alzheimer disease patients. Alzheimer Dis Assoc Disord. 2002; 16: 128-130.
44. McManus DQ, Arvanitis LA, Kowalcyk BB: Quetiapine, a novel antipsychotic: Experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group. J Clin Psychiatry. 1999; 60: 292-298.
45. Tariot PN, Salzman C, Yeung PP, et al.: Long-term use of quetiapine in elderly patients with psychotic disorders. Clin Therap. 2000; 22: 1068-1084.
46. Ballard C, Margallo-Lana M, Juszczak E, et al: Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: Randomised double blind placebo controlled trial. BMJ. 2005; 330: 874.
47. De Deyn P, Jeste DV, Swanink R, et al: Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: A randomized, placebo-controlled study. J Clin Psychopharmacol. 2005; 25: 463-467.
48. Baskys A: Lewy body dementia: The litmus test for neuroleptic sensitivity and extrapyramidal symptoms. J Clin Psychiatry. 2004; 65(Suppl 11): 16-22.
49. Mulsant BH, Gharabawi GM, Bossie CA, et al.: Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. J Clin Psychiatry. 2004; 65: 1708-1714.
50. Gareri P, Cotroneo A, Lacava R, et al.: Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia (BPSD). Arch Gerontol Geriatr Suppl 2004; 9: 207-215.
51. Fontaine CS, Hynan LS, Koch K, et al.: A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. J Clin Psychiatry. 2003; 64: 726-730.
52. Schneider LS, Tariot PN, Lyketsos CG, et al.: National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. Am J Geriatr Psychiatry. 2001; 9: 346-360.
53. McShane R, Keene J, Gedling K, et al.: Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. BMJ. 1997; 314: 266-270.
54. Saxton J, McGonigle-Gibson K, Swihart A, et al.: Assessment of severely impaired patients: Description and validation of a new neuropsychological test battery. Psychol Assess. 1990; 2: 298-303.
55. http://www.fda.gov/cder/drug/advisory/antipsychotics.htm. Accessed April 11, 2005.
56. Schneider LS, Dagerman KS, Insel P: Risk of death with atypical antipsychotic drug treatment for dementia. Meta-analysis of randomized placebo-controlled trials. JAMA. 2005; 294: 1934-1943.
57. Wooltorton E. Risperidone (Risperdal): Increased rate of cerebrovascular adverse events in dementia trials. Can Med Assoc J. 2002; 167: 1269-1270.
58. Wooltorton E. Olanzapine (Zyprexa): Increased incidence of cerebrovascular events in dementia trials. Can Med Assoc J. 2004; 170: 1395.
59. Abilify package insert. Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.; 2005.
60. Herrmann N, Lanctôt KL. Do atypical antipsychotics cause stroke? CNS Drugs. 2005; 19: 91-103.
61. Sleeper RB: Antipsychotic dose-sparing effect with addition of memantine. Ann Pharmacother. 2005; 39: 1573-1576.
62. Zhao Q, Xie C, Pesco-Koplowitz L, et al.: Pharmacokinetic and safety assessments of concurrent administration of risperidone and donepezil. J Clin Pharmacol. 2003; 43: 180-186.
63. Weiser M, Rotmensch HH, Korczyn AD, et al.: A pilot, randomized, open-label trial assessing safety and pharmacokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances. Int J Geriatr Psychiatry. 2002; 17: 343-346.
64. Huang F, Lasseter KC, Janssens L, et al.: Pharmacokinetic and safety assessments of galantamine and risperidone after the two drugs are administered alone and together. J Clin Pharmacol. 2002; 42: 1341-1351.